Important note: Information in this article was accurate in 2003. The state of the art may have changed since the publication date.
PRNewswire - November 17, 2003
In clinical trials, children who received VIRUCORT 50 in combination with anti-HIV medications demonstrated favorable results in depression symptoms, certain immunological improvements, and a resumption of HIV-stunted growth and weight gain.
The main ingredient of VIRUCORT 50 is Procaine HC1; reported in the medical press to be a reversible, selective inhibitor of monoamine oxidase (MAO), the "enzyme of depression," and affecting positively three neurotransmitters -- serotonin, norepinephrine (NE) and dopamine.
VIRUCORT is an antidepressant used in the treatment of HIV+ children, and is practically devoid of any side effects even after being administered for many months.
The VIRUCORT results seem to confirm articles published in the medical press which indicate that depression and depression-induced impaired immune systems are factors contributing to the progression of patients from HIV to AIDS, and conversely, that by treating these conditions, the slide into AIDS might be delayed or even prevented.
Worldwide there are 40 million HIV and AIDS patients; of these, around 3 million are children. From the total of 40 million, 36 million are HIV+ and millions of them are continually crossing the barrier to become AIDS patients, including a great number of children.
VIRUCORT 50 was developed by Alfred Sapse, MD(r), a Romanian born U.S. scientist and a Las Vegas resident, together with a Romanian team of scientists and physicians. Clinical trials were done by a team that included Prof.dr. Augustin Cupsa, Dr. Paul Marinescu, Prof.dr. Nicolae Voiculetz, and the experimental and pharmaceutical studies were performed and developed in the National Institute for Chemical-Pharmaceutical Research and Development (ICCF) in Bucharest, Romania, under the direction of dr. Sultana Nita; general coordinator, of the Romanian team was Prpf. dr. Sabin Cinca.
VIRUCORT 50 is available for marketing in Romania and soon thereafter, in other interested countries.
For further information, please contact: Aristide Buhoiu, Public Relations, +40.(0)72454l731, or fax, +40.21.312.24.27, universul@rdsnet.ro, for Cortisol Research International SA, Romania; or Alfred Sapse, MD, of Cortisol Research International SA, Romania, +1-702-734-6413, or fax, +1-702-733-9505, asapse@dralfredsapse.com, http://www.dralfredsapse.com .
SOURCE Cortisol Research International SA, Romania
Web Site: http://www.dralfredsapse.com
031117
PR031132
Copyright © 2003 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .